Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019

2019-09-11
Download

On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event in Malmö. The presentation will be held at Clarion Hotel & Congress Malmö Live and Ascelia Pharma will start its presentation at 6pm CET.

The presentation can also be followed live via: https://www.redeye.se/live/inv-aw-malmo-12-9

Program and registration for the event can be found here: https://www.redeye.se/events#/event/583611


For more information, please contact:
Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 9.15am CET on 11 September 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

2021-01-14

Information regarding transfer of shares in Ascelia Pharma AB from CMC SPV

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) today announced that it has been informed of that CMC SPV of 3 April 2017 AB (“CMC SPV”) today has divested 687,606 shares in the Company in a private placement to institutional investors and distributed 2,250,000 shares in the Company to its shareholders, including Sunstone and certain members of the board of directors and management of Ascelia Pharma. Followi ...
2021-01-12

Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral development plan can be found on its dedicated website.
2020-12-15

Ascelia Pharma gets US patent for second generation Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further improves the unique value proposition of the Mangoral franchise and provides patent protection until year 2040 in the US.